Visual Podcast: Expert Tips For Staving Off De Novo Troubles
This article was originally published in The Gray Sheet
King & Spalding's Quynh Hoang offers device manufacturers a handful of tips for pursuing de novo classification submissions – including urging firms to determine whether clinical studies are needed for a potential de novo submission – in this "Gray Sheet" podcast.
You may also be interested in...
FDA granted more than double the number of de novo petitions in FY 2013 compared to past years, reflecting the availability of the direct de novo pathway recently established by Congress. De novo petitions allow a device that FDA deems to be low-to-moderate risk but without a clear predicate to enter the market without requiring a PMA.
Italy Round-Up: Mylan And Polifarma Strike Deal, OTC Market Stable, Cholesterol-Lowering Probiotic Launch
The latest news from Italy's OTC and supplements markets, including the latest sales figures, business deals, product launches, ad regulation and local association activities.
Sandoz CEO Richard Saynor has pledged that the company will ensure stable pricing for essential coronavirus-related medicines amid concerns over how the outbreak will affect the supply chain.